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NOAH THORNTON: Serine and Glutathione Biosynthesis in Breast Cancer Subclones That 
Preferentially Metastasize to Lung and Bone  
(Under the direction of Dr. Mika Jekabsons) 
 
 
Metastatic breast cancers show distinct preferences to metastasize to lung and bone tissue. Transcriptomic 
analysis of lung-specific (LM) and bone-specific (BoM) subclones derived from the MDA-231 breast 
cancer line have identified differential expression of genes that may mediate this tissue-specific 
metastasis, but metabolic differences have not been systematically studied. If common metabolic 
phenotypes emerge in metastatic cancers having preferences for different organs, then such ‘metabolic 
plasticity’ may offer new therapeutic targets for treatment of specific metastases. Changes in glutathione 
(GSH) and serine synthesis may contribute to tissue-specific proliferation because of their roles in redox 
homeostasis, biosynthetic reactions including nucleotide synthesis, and/or energy metabolism. This study 
tests the hypothesis that glucose flux to serine, serine flux through the folate cycle, and glutamine flux to 
GSH differ between the parent MDA-231 breast cancer line, the LM and BoM lines, and the less 
malignant T47D breast cancer line. Using a combination of approaches including analysis of 13C serine 
enrichment from [1,2-13C] glucose by mass spectrometry and metabolic flux analysis, LM and BoM lines 
exhibited greater rates of serine synthesis than the T47D line, while there was no flux of glucose to serine 
in MDA-231 cells. Notably, LM and BoM serine synthesis was sufficiently high to negatively affect 
glycolysis, presumably through the NADH:NAD ratio. Folate cycle fluxes in LM and BoM lines were 
generally greater than those in T47D cells, as determined by metabolic flux analysis; these fluxes could 
not be determined in MDA-231 cells since glucose was not used to synthesize serine. LM cells exhibited 
no detectable GSH synthesis, while approximately 10% of the glutamine consumed by the other three 
lines was used for GSH synthesis, as determined by BSO-sensitive glutamine consumption. Higher 
glucose flux to serine in the BoM and LM lines are likely related to their higher proliferation rates rather 
 5 
than their specificity for metastasis to bone or lung. The lack of BSO-sensitive glutamine consumption in 
LM cells was surprising, and implies that this cell line may rely more on peroxiredoxin and/or thioredoxin 
than GSH for redox homeostasis. Further studies with different lung and bone-specific cancer lines are 
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Cancer is characterized by unregulated cell growth and proliferation, and altered fluxes through a number 
of metabolic pathways involved in energy production and biosynthetic processes necessary to support this 
phenotype (1, 2). However, unique metabolic signatures associated with heterogeneity of the tumor 
microenvironment within an organ (e.g., regional differences in hypoxia within a solid tumor) or, in the 
case of metastatic cancers, between different organs (e.g., differences in mass-specific blood flow and/or 
metabolism of each organ) are known to occur (3, 4). Reprogramming of cancer metabolism either during 
cancer progression or metastasis, a concept known as metabolic plasticity, may facilitate tumorigenesis or 
preferential metastasis to a specific organ (5). The triple-negative breast cancer cells (no expression of 
estrogen receptor, progesterone receptor, or human epithelial receptor 2), MDA-MB-231, have a different 
metabolic phenotype upon intravasation, indicating that the relatively few cells leaving the primary tumor 
may have differing metabolic properties from the majority of cells within the primary breast tumor (5). 
The environment in which cancer cells reside may provide selective pressures, such as limited availability 
of select nutrients or variations in oxygen and/or carbon dioxide content, that either drive metabolic 
adaptations or determine which subset of metabolically aberrant cells successfully metastasize to a 
specific secondary organ (6). Irrespective of whether metabolic plasticity is a stochastic process driven by 
genomic instability in proliferating cells within the primary tumor or by selective pressures after invasion 
of a secondary organ, an understanding of the specific metabolic signatures of tumor sub-clones that 
preferentially invade a specific organ is required to identify potential targets for the development of 
organ-specific metastasis therapies. 
Transcriptomic profiling has shown that sub-clones of metastatic tumors that preferentially invade 
different organs have different gene expression profiles (7). Therefore, individual cells within the MDA-
MB-231 metastatic breast cancer line are genetically heterogeneous. This heterogeneity contributes to the 
probability of specific metastasis to the lungs, bone, or brain by MDA-MB-231 cells (8). Experiments 
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using bioluminescence imaging have revealed that MDA-MB-231 cells isolated from the lungs, bones, or 
brain and then expanded in vitro, exhibit a high probability of selectively invading the same organ from 
which they were derived following re-injection into the circulatory system of nude mice (7). The isolation 
of highly lung-, bone-, and brain-specific metastatic subclones from the parent MDA-MB-231 line has 
provided insight on genes that contribute to organ specific metastasis.  Breast cancers that metastasize to 
the lungs over-express 50 genes that are directly and almost exclusively correlated with lung metastasis (9 
& 10). Similarly, there are many genes unique to bone-specific metastasis, with limited overlap between 
the genes that support the invasion of bone and lung tissue (9, 11). Breast cancer cells have been proven 
to require specialized function, potentially mediated through gene expression, in order to colonize in brain 
tissue, furthering the point of tissue-specific, varied environments giving rise to different metastatic 
speciations as well (9). Although the majority of these genes have a role in cell signaling, proliferation, 
and immune responses, the transcriptomic analysis was incomplete so the role of metabolic genes in this 
process remains unclear.  
Common metabolic changes among cancer cells arise from de-regulated anabolic pathways, glycolysis, 
and the uptake of nutrients; glucose and glutamine are the two primary nutrients which support survival 
and biosynthesis. The Warburg effect, discovered by Otto Warburg, details that even in the presence of 
oxygen, cancer cells metabolize glucose to lactate at extremely high rates, as opposed to the complete 
oxidation of glucose to carbon dioxide by the more efficient ATP production mechanism of oxidative 
phosphorylation (OXPHOS; 1). This effect, also known as aerobic glycolysis, is thought to increase the 
supply of glycolytic intermediates, which may be used in myriad of biosynthesis pathways (Fig. 1). 
Beyond these difference with untransformed cells, there is often notable variation of metabolic pathways 
within different cancers. Although glucose and glutamine are important for growth in most cancer cells, 
the fraction used by each anabolic pathway may vary depending on the local microenvironment in which 
the cancer cells reside. For example, the fraction of glucose used by the pentose phosphate pathway, fatty 
acid synthesis, serine synthesis, or oxidation by the mitochondria can vary depending on reactive oxygen 
species (ROS) production, availability pf biosynthetic substrates, ATP demand, uptake capacity of fatty 
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acids, and mitochondrial function. Similarly, glutamine used for protein, glutathione, or fatty acid 
synthesis, and for oxidation by the tricarboxylic acid (TCA) cycle and/or malic enzyme can vary 
depending on ROS production and availability of other substrates. Therefore, transcriptomic changes, 
energy demands, as well as prevailing microenvironment conditions likely play a role in the metabolic 
adaptations metastatic cancer cells develop as they progress from the parent tumor to their secondary sites 
of metastasis (12). 
 
Figure 1: A simplified map of cancer metabolism, including glycolysis and the tricarboxylic acid cycle (TCA). The experiments 
in the current study are part of a larger set of experiments designed to quantify fluxes through all the indicated reactions. The 
reactions are linked together through the shared intermediates indicated by grey boxes. Fluxes highlighted in red and purple are 
measured; all other fluxes are inferred. For the current study, the objective was to determine fluxes from 3-phosphoglycerate 
(3PG) to serine (J19), and glutamate (Glu) flux the glutathione (GSH). Cells were given [1,2-13C] glucose, and 13C enrichment in 
serine (M-M3) and lactate (M-M3) and serine export from the cells (J22) determined to quantify J19 and folate cycle fluxes (J21 
and other fluxes not shown) by computational modeling. Measurements of glucose uptake (J0), lactate production (J4), and 
mitochondrial respiration (JRR) provided constraints in the model. Pharmacological inhibition of GSH synthesis with buthionine 
sulfoximine was used to assess J18 by reduction in glutamine (Gln) uptake (J10).  
 
Enhanced aerobic glycolysis and glucose uptake in part reflect the importance of glycolysis for de-novo 
synthesis of nucleotides, amino acids, lipids, and reducing equivalents such as NADPH, all of which are 
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necessary for cell proliferation (4). Cancer cell proliferation is controlled by the availability of ATP as 
well as multiple intermediates that serve as substrates for the synthesis of lipids, nucleic acids, and 
proteins necessary to bolster the expanding biomass (13). Specifically, the oxidative and non-oxidative 
pentose phosphate pathways (J1 and J3f/r in Fig. 1) are responsible for providing pentose sugars for the 
biosynthesis of nucleic acids, and it is directly connected to glycolysis through the hexose phosphate 
(HxP; glucose-6-phosphate and fructose-6-phosphate) and triose phosphate (TrPs; glyceraldehyde-3-
phosphate and dihydroxyacetone phosphate) pools. Similarly, glycolysis produces 3-phosphoglycerate, 
which is a key cellular intermediate towards synthesis of various amino acids, such as serine and glycine, 
as well as purine nucleotides through one carbon metabolism in the folate cycle (12). The folate cycle 
produces glycine and cysteine, which are components of GSH, through re- and de-methylation reactions, 
purine units, necessary for nucleotide and ATP/GTP generation, and NADPH, involved in redox 
regulation. Serine is a major donor of one-carbon units into the folate cycle, making it implicated in these 
biosynthetic processes (14). The de-novo synthesis of serine from 3PG is initiated by the enzyme 
phosphoglycerate dehydrogenase (PHGDH), which has been implicated in cancer progression and/or 
metastasis due to its elevated expressions in some cancers (15). Cancer cells must synthesize nucleotides 
at a high rate for continued replication of the genome, and thus require a steady supply of glycolytic 
intermediates that can be used in the biosynthetic pathways that fuel their growth and proliferation (4). 
One focus of the current study is to assess potential differences in serine synthesis and folate cycle fluxes 
in breast cancer subclones preferentially metastasizing to lung or bone tissue. 
Similarly, increased glutaminolysis, the breakdown of glutamine into various metabolites, is a trademark 
feature of cancer cells, which supports the need for increased glutamine uptake in cancer cells (16). 
Glutamine is deaminated to glutamate and subsequently oxidized to a-ketoglutarate, a TCA cycle 
intermediate which contributes to ATP production and synthesis of fatty acids and cytochromes (16). 
DNA synthesis is constrained by glutamine availability in some cancers, reinforcing the idea of glutamine 
as an obligate nitrogen donor for purine and pyrimidine synthesis for nucleotides (16). Fatty acid 
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synthesis, necessary for the production of new cell membranes, is also fueled by glutamine through a-
ketoglutarate and subsequent reductive carboxylation to citrate (3). Lastly, glutamine, through conversion 
to glutamate, is also used in the de-novo synthesis of glutathione, an endogenous antioxidant (16).  
Redox homeostasis, the balance of reactive oxygen species (ROS) levels, plays an important role in cell 
survival (3). ROS are intracellular chemical species that, when at high levels causing oxidative stress, 
become exceedingly lethal by damaging DNA, proteins, and lipids. (17). The high aerobic glycolysis flux 
coupled with low mitochondrial activity that characterizes many cancers are conditions that may promote 
elevated ROS levels, which can induce oxidative stress (18). Moreover, breast cancer sub-clones that 
preferentially metastasize to lung may be subjected to greater oxidative stress and thus have a greater 
demand for glutathione. However, at low levels, ROS have been shown to oxidize cysteineresidues in 
various proteins to induce proliferative signals (3).  Antioxidants, such as glutathione (GSH), serve as a 
cofactor in reactions catalyzed by glutathione peroxidase and glutaredoxin that, respectively, reduce 
hydrogen peroxide to water and maintain protein thiols in their reduced state. A second focus of the 
current study is to determine if GSH synthesis from glutamine differs between breast cancer sub-clones 
that preferentially metastasize to lung and bone. 
Breast cancer sub-clones that preferentially metastasize to lung or bone tissue (designated LM and BoM 
cells, respectively) exhibit greater proliferation rates than the parent MDA-231 cells and the less 
malignant T47D breast cancer line. Such differences suggest the demand for nucleotides and amino acids 
differ among these lines. Furthermore, differences in the partial pressure of oxygen within the 
microenvironments preferred by these lines suggests potential their capacities for antioxidant defenses 
may vary. This study aims to quantify fluxes through the pathways that synthesize serine and GSH as 
well as the folate cycle. We hypothesize that the more proliferative BoM sub clone will exhibit greater 
serine biosynthesis from glucose than the LM, parent MDA-231, and less malignant T47D lines because 
of the limited blood flow, and hence serine supply, to bone tissue. LM and BoM lines are hypothesized to 
exhibit greater flux of serine into the folate cycle to support their higher proliferation rates than the MD-
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231 and T47D lines. Additionally, LM cells are hypothesized to exhibit a higher flux of glutamine to 
































Glutamate pyruvate transaminase, glucose-6-phosphate dehydrogenase (G6PDH), lactate 
dehydrogenase, oxidized and reduced forms of nicotinamide adenine dinucleotide phosphate (NADP(H)), 
adenosine triphosphate (ATP), and 2-oxoglutarate were purchased from Calzyme (San Luis Obispo, CA). 
Hexokinase, microbial glutamate dehydrogenase, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
(EDC), 3-nitrophenylhydrazine (NPH), buthionine sulfoximine (BSO), and CBR-5884 were purchased 
from Sigma (St. Louis, MO). 6-Aminoquinolyl-N-hydroxysuccinimidyl Carbamate (AQC) was purchased 
from Toronto Research Chemicals (Toronto, Canada). Glutaminase was purchased from Megazyme 
(Chicago, IL). [1,2] 13C glucose was purchased from Cambridge Isotopes (Tewksbury, MA). Cell culture 
media, fetal bovine serum, and cell culture supplies were purchased from Fisher Scientific (Pittsburg, 
PA). Buffers and other general reagents were purchased from Sigma (St. Louis, MO) 
B. Cell lines  
Metastatic breast cancer MDA-MB-231 cells (hereafter referred to as MDA-231) and the less 
aggressive T47D breast cancer cells were provided by Dr. Y.D. Zhou (University of Mississippi, 
Department of Chemistry and Biochemistry). Sub-clones of MDA-231 cells that preferentially 
metastasize to lung (LM) and bone (BoM) were generated by Massague’s lab (10,11). Both LM and BoM 
cells were obtained from Dr. Kounosuke Watabe (Wake Forest University) and provided by Dr. Zhou. 
Cells were routinely cultured using RPMI-1640 media supplemented with 10% fetal bovine serum and 
0.5% vol/vol penicillin-streptomycin in 10 cm polystyrene petri dishes at 37oC in a humidified 5% CO2 






C. Pharmacological Experiments with BSO and CBR-5884   
Cells were seeded in 2-well Lab-Tek II chambers (0.9-1.2 x 106 cells per well) and maintained at 
37oC/5% CO2 in RPMI medial supplemented with 10% fetal bovine serum and 0.5% 
penicillin/streptomycin one day prior to experiments. Cells were washed in experimental buffer 
containing 137 mM NaCl, 5 mM KCl, 20 mM TES,  1.3 mM CaCl2, 1.3 mM MgCl2, 1.2 mM Na2SO4, 0.4 
mM KH2PO4, 0.2 mM NaHCO3, 5.5 mM glucose, 0.3 % fatty acid-free bovine serum albumin (BSA), 1.5 
mM glutamine, pH 7.4  (hereafter referred to as experimental buffer). supplemented with 50 µM BSO or 
40 µM CBR-5884; control buffers were supplemented with water (for BSO) or DMSO (for CBR-5884) as 
vehicle. For some CBR-5884 experiments, glutamine was omitted from the buffer. The cells were 
equilibrated at 37 oC for 2 hr (BSO) or 2.5 hr (CBR-5884) to allow for inhibition of de-novo glutathione 
or serine synthesis, respectively. Cells were washed once then serially incubated with 350 µL at 37°C for 
1 x 60, 1 x 120, 1 x 60 minutes (for BSO) or 3 x 60 min (for CBR-5884). Control wells without cells were 
run in parallel to account for changes in buffer concentrations of glucose and glutamine by evaporation. 
The buffer samples were centrifuged for 5 min, 21,000 xg, at 4°C to remove any cells. The supernatant 
was then stored at -20°C for analysis of glucose and glutamine. Following the final incubation, cells were 
washed once with 1 mL of Phosphate Buffered Saline (PBS) and then solubilized with 20 mM TES pH 
7.3, 50 mM NaCl, and 1% SDS for 15 min at 37°C. The extracts were vortexed vigorously for 2 min, and 
then centrifuged for 10 min, 21,000 xg, at 10°C. The supernatants were stored at -20°C for analysis of 
total protein content.   
 
 
     
D.  Experiments with [1,2-13C] glucose  
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Cells were seeded in 2-well Lab-Tek II chambers (0.9-1.2 x 106 cells per well) and maintained at 
37oC/5% CO2 in RPMI media supplemented with 10% fetal bovine serum and 0.5% 
penicillin/streptomycin one day prior to experiments. For each experiment, either T47D and MDA-231 
cells or LM and BoM cells were seeded in separate wells of the chamber. The cells were washed once in 
137 mM NaCl, 5 mM KCl, 20 mM TES pH 7.4, 1.3 mM CaCl2, 1.3 mM MgCl2, 1.2 mM Na2SO4, 0.4 
mM KH2PO4, 0.2 mM NaHCO3, 5.5 mM [1,2-13C] glucose, and 0.3 % fatty acid-free bovine serum 
albumin (hereafter referred to as 13C experimental buffer) then incubated in 1000 µl of 13C experimental 
buffer for 5 h at 37oC to allow glycolytic and TCA cycle metabolites to reach steady-state isotopic 
labeling; buffer was exchanged once during the equilibration period. Respiration rate of each well was 
measured at 37oC in 2.15 ml of fresh 13C experimental buffer using a Clark-type micro-oxygen electrode 
(Microelectrodes, Inc., Bedford, MA) positioned above the chamber with a custom-made lid. The oxygen 
concentration in each well was acquired over 45-55 min. with a Powerlab A/D unit and Lab Chart 
software.  In total the cells were pre-equilibrated for approximately 6.5 h prior to incubations for 
assessing 13C enrichment in serine and lactate. Cells were washed once then incubated for 2 x 60 min 
intervals at 37oC with 350 µl experimental buffer; after the first interval, cells were washed once and 
given fresh buffer. Control wells without cells were run in parallel to correct for evaporation over each 
incubation interval. Buffer samples were centrifuged 5 min, 4oC and 21,000 xg; the supernatants were 
stored at -20oC for analysis of 13C enrichment in extracellular lactate and serine. 
E. Lactate derivatization and mass spectrometry analysis  
The samples and M/M1 lactate standards prepared in experimental buffer (18 µL) were extracted 
with 2 volumes 100% cold methanol and then incubated for 1 h at -20°C to precipitate buffer proteins. The 
samples were centrifuged at 21,000 xg, 2°C for 10 min. The supernatants (54 µL) were derivatized by 
incubation with 27 µL50 mM N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide (prepared fresh in 1.5% 
pyridine, 98.5% ethanol) and 27 µl 140 mM 3-nitrophenylhydrazine (prepared fresh in 50% ethanol) for 2 
h at 37°C, cooled on ice, then diluted 1:50 in mass spec vials with 80% methanol for analysis by liquid 
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chromatography-triple quadrupole mass spectrometry. Both unlabeled (M), 13C labeled (M1), and 66:1 
M:M1 mixed lactate standards were run to confirm the expected masses (224 Da for M, 225 Da for M1) 
and verify separation of these isotopologues.  
The derivatized samples were separated on a Waters ACQUITY I-Class UPLC™ system including 
binary solvent manager, sample manager and column manager connected to a Waters Xevo TQ-S triple 
quadrupole mass spectrometer (Waters Corp, Milford, MA, USA). The separation was carried out on a 
Waters Acquity UPLC™ BEH C18 column (50mm × 2.1mm i.d., 1.7 µm). The sample temperature and 
column temperature were maintained at 10 °C and 40 °C, respectively. The mobile phase consisted of water 
containing 0.1% formic acid (v/v) (A) and acetonitrile with 0.1% formic acid (B). The analysis was 
performed using the following gradient elution at a flow rate of 0.50 mL/min: 0-2.5 min, 5% B to 18% B; 
2.5-3 min, 18% B to 100% B. Each run was followed by a 2.5 min wash with 100% B and an equilibration 
period of 2.5 min with the initial conditions. The strong and weak solutions used to wash the auto sampler 
were methanol/acetonitrile/isopropanol/water (25:25:25:25, v/v/v/v/v) and methanol/water (70:30, v/v), 
respectively. The injection volume was 1 µl. The UHPLC effluent was introduced into the Waters Xevo 
TQ-S mass spectrometer equipped with electrospray ionization in negative ion mode (ESI-) for 
quantification of the analytes. Detection was obtained by Multiple Reaction Monitoring (MRM) mode 
including two MRMs for confirmation of the analytes. MRM transitions and related parameters are listed 
in Table 1. The quantification of analytes 224, 225, 226, and 227 (the expected masses for M, M1, M2, and 
M3 lactate derivatized with nitrophenylhydrazine, respectively) was acquired with transitions of 
deprotonated ion at m/z 224.04 → 152.06 for M, 225.04 → 152.06 for M1, 226.04 → 152.06 for M2, and 
227.04 → 152.06 for M3 with dwell time of 20 msec at cone voltage 44 V and collision energy 14 eV for 
each transition. The ESI–MS/MS parameters were set as follows: capillary voltage, 1.20 kV; cone voltage, 
44 V; source temperature, 150 °C; desolvation temperature, 600 °C; desolvation gas flow, 600 L/h, cone 
gas flow, 200 L/h. Nitrogen was used as desolvation and cone gas. Argon (99.99% purity) was introduced 
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as the collision gas into the collision cell at a flow rate of 0.15 mL/min. Data acquisition was carried out by 
MassLynx 4.1 software and processed by TargetLynx (Waters Corp., Milford, MA, USA). 
 













M 224.04 224.04 -> 152.06 






M1 225.04 225.04 -> 152.06 






M2 226.04 226.04 -> 152.06 






M3 227.04 227.04 -> 152.06 









F. Serine Derivation and Mass Spectrometry Analysis 
The samples and serine standards in experimental buffer (20 µL) were extracted with 10 µL of 
0.6 M trichloroacetic Acid (TCA) for 30 min on ice and then centrifuged for 10 min, 21,000xg, at 4℃. An 
aliquot of the supernatant (12 µL) was neutralized with 36 µL of sodium borate (pH = 9.3). Stock 10 mM 
 21 
AQC was prepared fresh in anhydrous acetonitrile by incubating for 10 min at 55℃. Primary and 
secondary amines in the neutralized samples were derivatized with 24 µL 10mM AQC for 10 min at 55℃. 
 
F.1. Serine Mass Spectrometry Analysis  
All analysis was performed on a Waters ACQUITY I-Class UPLC™ system coupled with a Waters 
Xevo TQ-S triple quadrupole mass spectrometer (Waters Corp, Milford, MA, USA). A Waters Acquity 
UPLC BEH C18 column (50 mm × 2.1 mm I.D., 1.7 µm) was used with a mobile phase composed of water 
containing 0.1 % formic acid (A) and acetonitrile with 0.1 % formic acid (B). Sample and column 
temperatures were maintained at 10 °C and 40 °C, respectively. The LC flow rate was 0.35 mL/min in a 
gradient elution as follows: 0-1.5 min, 2% B to 20% B; 1.5-2.0 min, 20% B to 100% B. Each run was 
followed by a 2 min wash with 100% B and an equilibration period of 3 min with the initial conditions. The 
wash and purge solvents used to wash the autosampler were methanol/acetonitrile/isopropanol/water 
(25:25:25:25, v/v/v/v) and methanol/water (50:50, v/v), respectively. The effluent is directly guided into 
Xevo TQ-S mass spectrometer equipped with electrospray ionization in a positive ion mode (ESI+). 
Multiple Reaction Monitoring (MRM) mode including two MRMs for each analyte were used for 
quantification and confirmation respectively. MRMs of analytes 276, 277, 278, and 279 (the expected 
masses for M, M1, M2, and M3 of serine derivatized with AQC respectively; all had 1.08 min retention 
time) were recorded. For quantification of serine AQC derivatives, MRM transitions of protonated ion use 
at m/z 276.05 > 171.06 for M, 277.05 > 171.06 for M1, 278.05 > 171.06 for M2, and 279.05 > 171.06 for 
M3. The dwell time was 6 ms for each transition at cone voltage 46 V and collision energy 46 eV. The 
ESI+ MS/MS parameters were set as follows: capillary voltage, 2.50 kV; cone voltage, 38 V; source 
temperature, 150 °C; desolvation temperature, 500 °C; desolvation gas flow, 1000 L/h, cone gas flow, 150 
L/h. Nitrogen was used as desolvation and cone gas. Argon (99.99% purity) as the collision gas was 
introduced into the collision cell at a flow rate of 0.15 mL/min. Data acquisition was carried out with 
MassLynx 4.1 software (Waters Corp., Milford, MA, USA).  
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F.  Protein Assay 
Determination of protein content in cell extracts (duplicates, diluted 1:3 in water) were 
determined by bicinchoninic acid (BCA) assay. 500 µL of BCA Reagent was added to 25 µL of diluted 
sample, and the reaction incubated for 30 min at 60℃, then cooled to room temperature before being 
quantitated at a 562 nm wavelength using a Ultrospec 3100pro spectrophotometer (Amersham 
Bioscience). 562 nm wavelength was used as the BCA reagent utilizes the reduction of Cu2+ to Cu1+ by 
protein, as BCA reacts with the reduced cation through chelation to form a BCA-Copper complex with a 
strong absorbance at 562 nm, which increases as protein concentration increases. Bovine Serum Albumin 
(BSA) standards (0, 50, 100, 150, 200, 300, 400, and 500 µg/ml) were dissolved in the same 
solubilization buffer as to prepare cell extracts and run alongside the test samples as standards of known 
protein content.  
 
 
G. Metabolite Assays 
G.1. Glucose Assay 
 The concentration of glucose remaining in the experimental buffer after incubation with cells was 
determined by enzymatic assay, and these concentrations were used to calculate glucose uptake rates. The 
samples and standards (5µl, in triplicate sets) were added to 115 µl of a reaction containing 100 mM 
triethanolamine pH 7.3, 7 mM MgCl2, 2mM ATP, 2 mM NADP, 1U/mL glucose-6-phosphate 
dehydrogenase, and 1 U/mL hexokinase. Hexokinase and ATP catalyze the phosphorylation of glucose to 
glucose-6-Phosphate, which is then oxidized by glucose-6-phosphate dehydrogenase concomitant with 
the reduction of NADP to NADPH, the latter of which is fluorescence. The samples were incubated 10 
min and the fluorescence was quantitated with a Shimadzu RF-6000 spectrofluoremeter (Ex=341 nm, 
Em=464 nm). Glucose standards (3.5, 4.0, 4.5, 5.0, 5.5, 6.0 mM) were run in the same buffer alongside 




G.2. Glutamine Assay 
 The concentration of glutamine in the experimental buffer after incubation with cells was 
determined by a two-step enzymatic reaction. The samples and standards (6µl, in duplicate) were added to 
34µl of buffer, containing 60 mM sodium acetate pH 4.5, and with or without 1 U/mL glutaminase. The 
glutaminase was added to cleave the amino group from glutamine, resulting in free ammonia and 
glutamate; control reactions without glutaminase were to assess background free ammonia in the samples. 
The duplicate samples were then incubated for 45 minutes at 37℃. The second enzymatic reaction as 
initiated by addition of 80µl reaction buffer containing 300 mM Tris pH 8.5, 10 mM 2-oxoglutarate, 240 
µM NADPH, and 2 U/mL glutamate dehydrogenase. The addition of glutamate dehydrogenase uses the 
free ammonia, generated via glutaminase, to reductively aminate 2-oxoglutarate to Glutamate, 
subsequently oxidizing NADPH, the fluorescent target, to NADP. These mixtures were then incubated in 
the dark for 80 min at room temperature, (approximately 20-25°C). Following the second incubation, the 
fluorescence of the duplicate samples were quantified using the Shimadzu RF-6000 
spectrolfluorophotometer (ex=341 nm, em=464 nm). Naturally occurring ammonia was controlled for by 
running the glutamine standards (0, 0.2, 0.4, 0.8, 1.2, 1.6, and 2.0 mM) without the presence of 
glutaminase, allowing us to subtract the fluorescence of NADPH of the cell samples from the standards.  
 
 
H. Folate Cycle Flux Calculations 
The folate cycle model (the basis for this model is in Figs. 1 and 5) has seven fluxes (J19 – J25), 
one of which (J22) is measured from LC-TQ mass spectrometry of serine. Three flux ratios are 
optimized by the model to reproduced the measured 13C serine labeling pattern: 
"#$
"#$%"&'
= 𝑋                                                                                (Eq. 1) 
"&#
"&#%"&*
= 𝑌                                                                                (Eq. 2) 
"&,
"#$%"&,
= 𝑍                                                                                (Eq. 3) 
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The BSO-sensitive glutamine uptake rate (Fig. 2), which together with the ratio of average 
glutamine to glucose uptake (𝐽/0
123 𝐽0
1234 ) from experiments with [5-13C] glutamine (unpublished) 
and the measured rate of [1,2-13C] glucose uptake (J0), were used to calculate a minimal estimate 







@AB ∗ 𝐽0                                                          (Eq. 4) 
This approach assumes that the glutamine demand normalized to glucose uptake without 
exogenous glutamine (experiments with [1,2-13C] glucose) is the same as that for cells given 1.5 
mM [5-13C] glutamine. With metabolic steady-state conditions, then the serine balance is: 
𝐽/C + 𝐽50 = 𝐽55 + 𝐽5/ − 𝐽5F                                                                     (Eq. 5) 
Substituting for J25 into Eq. 5 using Eq. 2: 
 𝐽/C + 𝐽50 =
"&&%"&#
/%G
                                                                      (Eq. 6) 
The glycine balance is given as: 
 𝐽5/ + 𝐽5H = 𝐽56 + 𝐽5F                                                             (Eq. 7) 
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                                                       (Eq. 9) 




∗ 𝐽5/                                                (Eq. 10) 
So from Eq. 6: 
  𝐽5F = 𝐽5/ + 𝐽5H − 𝐽56                                                  (Eq. 11) 
Substituting the expression for J19 + J20 in Eq. 5 into Eq. 1, then: 
𝐽/C = 𝑋 ∗ (𝐽55 + 𝐽5/ − 𝐽5F)                                                                    (Eq. 12) 
  
and  𝐽50 = 𝐽55 + 𝐽5/ − 𝐽5F − 𝐽/C                                                                   (Eq. 13) 
For cells lacking BSO-sensitive glutamine uptake (LM line; see Fig. 2), J19 was estimated as 
that necessary to support J7 (by production of NADH) so that the error between the measured 
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and model-calculated 13C lactate labeling patterns was minimized (see Tables 2 and 3). 




∗ 𝐽/C                                                                (Eq. 14) 
From Eq. 3: 
𝐽5F = 𝑍 ∗ (𝐽/C + 𝐽50)                                                                (Eq. 13) 


































A. Glutamine used for de-novo glutathione biosynthesis.  
Many tumor cells have elevated proliferation rates, and glutathione (GSH), a potent antioxidant 
and cell proliferation modulator, is associate with increased proliferation rates (19).  Buthionine 
sulfoximine (BSO) is a synthetic amino acid analog that specifically inhibits gamma-glutamylcysteine 
synthetase, which is the enzyme that catalyzes the initial step of de-novo glutathione biosynthesis by 
converting L-glutamate to gamma-glutamyl cysteine, a precursor to glutathione (20). For these 
experiments in which the buffer was not supplemented with glutamate, exogenous glutamine is a 
significant source of glutamate through a deamination reaction catalyzed by the mitochondrial localized 
enzyme glutaminase. Therefore, BSO is expected to reduce glutamine demand and thus its uptake from 
the extracellular media for cells actively synthesizing GSH. This BSO-sensitive glutamine consumption 
thus provides a lower-limit estimate of GSH biosynthesis (Fig. 1, flux J18). Pre-treatment for 2 h with 
BSO significantly reduced glutamine uptake rate measured over two one-hour intervals in the MDA-231 
and BoM lines, and tended to reduce uptake in T47D cells (p=0.107), but was without effect in the LM 
line (Fig. 2A). The BSO-sensitive fraction of glutamine consumption was similar for MDA-231, BoM, 
and T47D lines (10.2±2.1, 8.8±3.4, and 13.5±7.3%, respectively; Fig. 2B); while there was no significant 
main effect of cell line on BSO-sensitive glutamine consumption (1-way ANOVA p=0.292), likely 
because of the low number of replicate experiments, the LM line notably differed with no indication of 
glutamine consumption for GSH synthesis.  
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Figure 2: BSO Sensitive Glutamine uptake rates (A) and fractional glutamine uptake for glutathione biosynthesis (B). Cell lines 
were pre-incubated in the presence or absence of 50 µM BSO for 2 h. The buffer glutamine concentrations were determined by 
enzymatic assay and the rates of uptake were averaged over two 60 min incubation periods. The rates were then normalized to 
total SDS-soluble protein. The data is presented as the mean ± standard error (n =3). Flux data in (A) were analyzed by one-
tailed T-test and fractional uptake in (B) by 1-way ANOVA. Asterisks indicate a significant effect (p<0.05) of BSO.  
 
 
B. Glucose Uptake to assess de-novo serine biosynthesis 
Glucose is a substrate used by tumor cells for a variety of homeostatic pathways, including energy 
through ATP synthesis, production of NADPH and NADH, and various anabolic processes, such as 
amino acid and nucleotide synthesis. Serine, which can be synthesized from glucose or obtained from the 
extracellular fluid, is an important amino acid necessary for protein synthesis, a source of glycine, as well 
as substrate for one-carbon metabolism in the folate cycle that is used for synthesis of purine nucleotides. 
The first step in de-novo serine biosynthesis is catalyzed by 3-phosphoglycerate dehydrogenase 
(PHGDH), the rate limiting enzyme that oxidizes 3-phosphoglycerate, a glycolytic intermediate, into 
phosphohydroxypyruvate, a precursor for serine with the concomitant reduction of NAD to NADH (13). 
 28 
Two further steps convert phosphohydroxypyruvate to serine, with glutamate being a required co-
substrate for the reaction catalyzed by phosphoserine aminotransferase.  PHGDH is an NAD-dependent 
dehydrogenase that has been shown to be upregulated in some tumor cells and inhibited non-
competitively by CBR-5884 (14, 21). For cancer cells synthesizing serine, demand for 3PG, and 
correspondingly supply of this substrate by glucose consumption through glycolysis, are predicted to 
decrease upon inhibition by CBR-5884; thus, the CBR-5884-sensitive reduction in glucose uptake can be 
taken as an estimate of 3PG flux to serine (Figs. 1 and 5, J19). Since glutamate is a required co-substrate in 
this pathway, experiments were run in buffer ± glutamine to determine if omission of this amino acid 
negatively affects serine synthesis by limitation in glutamate availability (see section C for experiments 
with [1,2-13C] glucose). None of the CBR-5884 treated cell lines exhibited a significant reduction in 
glucose consumption, either without (Fig. 3A) or with (Fig. 3B) glutamine. Unexpectedly, glucose 
consumption was higher in CBR-5884-treated LM and BoM lines (with glutamine, p= 0.030 and 0.021 
for BoM and LM, respectively; without glutamine p= 0.019 and 0.176, respectively). The increased 
glucose consumption tended to be higher without glutamine (14.0±2.6% and 11.2±9.6% for BoM and 
LM, respectively) than with glutamine (3.5±0.9% and 3.8±0.8% for BoM and LM, respectively (Fig. 3C, 
3D), which suggests that the absence of exogenous glutamine does not limit serine synthesis. The low 
number of replicates (n=3) and inherent assay error can account for a lack of statistical significance 
between the cell lines in the average fraction of glucose used for serine synthesis (one-way ANOVA p= 
0.153 without glutamine and 0.567, with glutamine). Given that serine synthesis yields NADH but no 
lactate, this pathway tends to increase the NADH/NAD ratio, which negatively regulates glycolysis; 
reduction in this ratio by inhibition of serine synthesis could thus account for the observed increase in 





Figure 3: CBR-5884-sensitive glucose uptake rates for cell lines incubated without (A) or with (B) supplemental glutamine in the 
media and fractional glucose uptake for serine biosynthesis without (C) or with (D) supplemental glutamine in the media. Cell 
lines were pre-incubated 2.5 h with 40 µM CBR-5884. The buffer glucose concentrations were determined by enzymatic assay 
and the rates of uptake were averaged over two 60 min incubation periods. The rates were then normalized to total SDS-soluble 
protein. The data is presented as the mean ± standard error of the mean (n =3). Flux data in (A) and (B) were analyzed by one-
tailed T-test and fractional uptake in (C) and (D) by 1-way ANOVA. Asterisks indicate a significant effect of CBR-5884 
treatment.  
 
C. 13C Enrichment in Serine and Lactate from [1,2-13C] glucose 
To further evaluate serine biosynthesis, cells were given [1,2-13C] glucose and the serine exported to the 
buffer was analyzed by liquid chromatography, triple quadrupole mass spectrometry (LC-TQ MS; Table 
2). 13C abundance in serine from MDA-231 cells was no different from background 13C, as measured with 
unlabeled serine standards (fractional labeling of standards: M=0.9517±0.0038, M1=0.0406±0.0033, 
M2=0.0076±0.0005, M3=0.0001±0.0001; n=5). In contrast, T47D, BoM, and LM cells showed 
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significant 13C enrichment above background, indicative of serine biosynthesis in these lines (Table 2). 
Additionally, the M2 and M3 labeling patterns of LM and BoM cells were significantly greater than that 
in T47D cells, while the M1 content tended to be greater cells (p=0.059 T47D vs. BoM, p=0.153 T47D 
vs. LM). These data suggest that the contribution of serine synthesis to labeling the intracellular serine 
pool and/or the activities of other pathways that rearrange the carbon atoms in serine may differ between 
these cell lines. From this analysis, the serine efflux rate (Fig. 5, J22) was calculated assuming that 
accumulation of this amino acid in the buffer over the 60 min incubation periods did not affect the rate of 
its export (Fig. 4). The LM and BoM cells tended to export serine at a lower rate than T47D cells (Fig. 4; 
p=0.048 LM vs. T47D; p=0.280 BoM vs. T47D). While these data provide convincing evidence for serine 
biosynthesis in T47D, LM, and BoM cells, quantitation of 3PG flux to serine (J19) requires additional 
information on the relative activities of other pathways involved in either consuming serine and/or 
rearranging the carbon atoms in serine. Glycolysis metabolizes 3PG to pyruvate, which is subsequently 
reduced to lactate that is exported from the cell. 13C lactate labeling can thus provide needed insight on 
3PG labeling, and hence on the potential activities of pathways that rearrange the carbon atoms in serine. 
13C lactate enrichment was determined by LC-TQ MS (Table 2) to infer 13C-labeling of 3PG, the 
glycolytic intermediate that is substrate for serine synthesis. The 3PG carbons are not rearranged in the 3-
step serine synthesis pathway, so in principle the labeling pattern in 3PG should be no different from that 
of serine. In order to infer 3PG labeling, a computational model was used  to reproduce the lactate 
labeling pattern by optimizing 3 flux ratios (Table 3) that have a major impact on 13C labeling in lactate 
for cells metabolizing [1,2-13C]glucose because of the carbon atom rearrangements that occur in these 
pathways (Fig. 6): the contribution of the pentose cycle to labeling the hexose phosphate pool 
(J3af/(J0+J3af), the contribution of malic enzyme to labeling the pyruvate pool (J7/(J2c+J7) and the 
contribution of the forward and reverse non-oxidative pentose phosphate pathway fluxes (J3af and J3ar, 
respectively) to labeling the ribose phosphate pool (J3af/J3ar). The development of this model has been 
described in detail elsewhere (22, 23). The model was reasonably effective at reproducing the measured 
lactate labeling patterns for each cell line, as the errors between the measured and predicted labeling were 
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small (Tables 2 and 3).  From this, the estimated 3PG labeling (Table 4) differed substantially from the 
serine labeling (Table 2) by having lower M and M1 contents and a higher M2 content. This suggests 
that, once synthesized, serine is subjected to a cyclic pathway that results in carbon rearrangements in the 
serine passing through the cycle. 
The folate cycle is the most obvious metabolic pathway that can account for carbon rearrangements in 
serine (Figs. 5 and 6). Since 3PG labeling was similar among the cell lines, but serine labeling differed 
significantly, this suggests flux through the folate cycle and/or serine synthesis pathway differs between 
the T47D, BoM, and LM lines. To quantitate these fluxes, a simplified model of the folate cycle was 
developed to solve for three flux ratios associated with serine synthesis and the cycle that affect 13C 
enrichment in the serine pool (Fig. 5). Note that because MDA-231 cells did not synthesize serine from 
glucose, it was not possible to analyze the folate cycle in this cell line. The inputs to the model were the 
13C labeling patterns in 3PG and serine, and the background 13C labeling of endogenous serine and 
glycine, as determined using unlabeled standards.  
 
Table 2: 13C Lactate and Serine enrichment from [1,2 13C]  glucose 
Cell Line Lactate M Lactate M1 Lactate M2 Lactate M3 Serine M Serine M1 Serine M2 Serine M3 




























































Unlabeled (M), single (M1), double (M2), and triple (M3) 13C labeled lactate and serine resulting from metabolism of 1,2 
13C   glucose was measured in the spent buffer by mass spectrometry. Standards were run in parallel to quantitate the metabolites 
and the data expressed as fractional content of each label. Data are the mean ± the standard error of six 
experiments. Differences between cell lines in the fractional content of each labeled species was determined by 1-way ANOVA 
with Tukey’s post-hoc test. Means sharing common superscripts within a column do not significantly differ. 
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Figure 4:  Serine efflux rates for each cell line measured by LC-TQ mass spectrometry over each 1 h incubation. Data are mean 
± standard error of the mean of six experiments. These rates reflect J22 in the metabolic maps shown in Figs 5 and 6. Data were 
analyzed by 1-way ANOVA and Tukey’s post-hoc test. Means sharing the same letter are not significantly different. 
 
Table 3: Model-predicted 13C Lactate Labeling with Model Error and Flux Ratios that were 
optimized 
Cell Line Lactate M Lactate M1 Lactate M2 Lactate M3 Model Error J3af/J3ar J3af/(J3af+J0) J7/(J7+J2b) 




























































Unlabeled (M), single (M1), double (M2), and triple (M3) 13C labeled lactate predicted by the computational model. 
Computational modeling was used to reproduce the labeling pattern of 13C in lactate within the constraints of the measured 
fluxes glucose consumption, lactate production, mitochondrial respiration rate.  Data are the mean ± the standard error of the 
mean from six experiments for each cell line. This table can be used to compare the predicted lactate labeling to the measured 
lactate labeling (Table 2) as well as to analyze the fluxes that were optimized to predict the labeling. The model error is the sum 
of the absolute values of the difference between the M-M3 predicted and measured labeling Flux ratios were analyzed by 1-way 





Table 4: Model-predicted 3-Phosphoglycerate 13C enrichment from 1,2 13C glucose 
Cell Line M M1 M2 M3 
LM 0.5102 ± 0.0005 0.0151 ± 0.0005 0.4739 ± 0.0009 0.0008 ± 0.00004 
T47D 0.5133 ± 0.0007 0.0208 ± 0.0009 0.4647 ± 0.0017 0.0011 ± 0.0001 
BoM 0.5105 ± 0.0014 0.0132 ± 0.0015 0.4759 ± 0.0030 0.0004 ± 0.0002 
MDA 0.5087 ± 0.0015 0.0078 ± 0.0007 0.4835 ± 0.0022 <0.0001 ± <0.0001 
Unlabeled (M), single (M1), double (M2), and triple (M3) 13C labeled 3-Phosphoglycerate predicted by the computational model 
whose optimized flux ratios are shown in Table 3. Data are the mean ± the standard error of the mean for each cell line.  
 
 
Figure 5: A simplified model of the folate cycle. Serine efflux and extracellular 13C serine labeling were measured by LC-TQ MS. 
3PG 13C labeling was inferred from modeling 13C lactate labeling. Serine consumption was assumed to occur through two 
processes- serine export from the cell and de-methylation to glycine, which in turn is used by various reactions, including 
glutathione synthesis. Endogenous sources of serine and glycine were assumed to be from protein turnover. Abbreviations: 3PG: 
3-phosphoglycerate, Serc: cytoplasmic serine, SerECF: extracellular serine, THF: tetrahydrofolate, mTHF: methyl-
tetrahydrofolate, Gly: cytoplasmic glycine. Flux notations: J19: serine synthesis from 3PG, J20: serine from protein turnover 
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contributing to cytoplasmic serine pool, J21: de-methylation of serine in the folate cycle by serine hydroxyl-methyltransferase, 
J22: serine export to the extracellular fluid, J23: cellular glycine consumption, J24: glycine from protein turnover contributing to 
the cytoplasmic glycine pool, J25: methylation of glycine to serine in the folate cycle. 
From the model, the optimized flux ratios affecting serine labeling are the contribution of serine 
synthesis to the cytoplasmic serine (J19/(J19+J20)), the contribution of the folate cycle to labeling of the 
cytoplasmic glycine pool (J21/(J21+J24)), and the fraction of serine that recycles through the folate cycle 
(J25/(J19+J20)). The great majority of the 3PG was either unlabeled or double-labeled (Table 4), with the 
latter labels largely occurring at carbons 2 and 3. The recycling of unlabeled and 2,3 labeled serine 
through the folate cycle will result in enrichment of M1 serine at the expense of M2 serine as carbon 3 is 
transferred to tetrahydrofolate (Fig. 6). The model was effective in reproducing the serine labeling 
pattern, as demonstrated by the extremely low errors (Table 5; and compare serine labeling with Table 2). 
It is notable that the T47D line differed from the BoM and LM lines, which is not surprising given that 
the M1 and M2 serine labeling in the T47D line tended to be lower than the BoM and LM lines. The 
contribution of serine synthesis to labeling the serine pool was higher in the more malignant LM and 
BoM lines, while the fraction of serine recycling through the folate cycle was significantly lower in these 
lines compared to T47D cells (Table 5).   
Table 5: Folate cycle model results 
 
Unlabeled (M), single (M1), double (M2), and triple (M3) 13C labeled serine predicted by the computational folate cycle model 
depicted in Fig. 5. Computational modeling was used to reproduce the labeling pattern of 13C in serine by optimizing three flux 
ratios: J19/( J19+ J20), J21/( J21+ J24), and J25/( J19+ J20).  Data are the mean ± the standard error of the mean of six experiments 
for each cell line. The model error is the sum of the absolute values of the difference between the M-M3 predicted and measured 
labeling. Flux ratios were analyzed by 1-way ANOVA with Tukey’s post-hoc test. Within a column, means sharing common 
superscripts are not significantly different.  























































Figure 6:  Carbon atom transitions within the folate cycle to predict its impact on serine labeling. Unlabeled carbon atoms are 
depicted as open circles and 13C carbons as filled circles. Carbons in serine (Ser) and glycine (Gly) are numbered from left to 
right. About half of the serine from biosynthesis is double-labeled at positions 2 and 3, while the other half and approximately 
96% of endogenous serine is unlabeled. As serine enters the folate cycle, carbon 3 is transferred to tetrahydrofolate (THF). The 
methyl group can be used for purine synthesis, in which case the resulting glycine affects the labeling of the cytoplasmic glycine 
pool. Alternatively, the methyl group can be transferred to glycine; the probability of 13C transfer to unlabeled glycine to form 
M1 serine is much greater than transfer to M1 glycine to form M2 serine because of the high proportion on unlabeled glycine. 
This enriches M1 serine and depletes M2 serine. The steady-state fractional labeling in serine was determined from twenty 
rounds of this cycle. 
 
E. Calculating Pathway Fluxes 
Determination of folate cycle fluxes required knowing at least two of the seven fluxes in addition to the 
flux ratios determined by the folate cycle model. Along with serine efflux (J22), a minimal estimate of 
glycine consumption (J23) can be assessed from the BSO-sensitive glutamine consumption seen for T47D 
and BoM lines since glycine is also required for GSH synthesis (see Methods for a detailed explanation). 
This approach was not possible for LM cells since they lacked BSO-sensitive glutamine uptake, but a 
minimal estimate of J19 was obtained from the 13C model employed to reproduce lactate labeling from 
[1,2-13C] glucose. Without serine synthesis, the model was inadequate for LM cells because malic enzyme 
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flux, which enriches M1 and M3 pyruvate, was limited by a combination of insufficient NADH from 
glycolysis and low mitochondrial respiration rate. Pyruvate produced by malic enzyme does not generate 
NADH, so another source of this reducing equivalent such as the serine synthesis pathway is required. 
Inclusion of a serine synthesis flux established by the model significantly reduced the error between the 
calculated and measured 13C lactate enrichment. This insight justifies quantitation of J19 in this way, and 
suggests that serine synthesis is an important controller of malic enzyme activity. 
Serine synthesis flux in T47D cells was minimal, consuming only 0.13±0.02% of glucose. Approximately 
22% of the serine supplied by J19 and J20 entered the folate cycle (J21) while 78% was exported; 1.6% of 
the serine entering the cycle returned to the serine pool (J25) and the rest was consumed for GSH 
synthesis. Serine metabolism in T47D cells has been previously investigated by Dolfi et al (24). From 
their results (personal communication with A. Vazquez), we calculated that T47D serine consumption for 
purposes other than protein synthesis was 3.42% of glucose consumption (consumption for protein 
synthesis was excluded since exogenous essential amino acids were not present in our experiments). 
Folate cycle fluxes calculated from this result were very similar to those based on BSO-sensitive 
glutamine consumption (J19= 31±3, J21 = 44±33, J23 = 305 ± 26, and J25 = 13 ± 4 pmol/min x mg; compare 
to Table 6).  
With the exception of serine export, fluxes in LM cells were more than an order of magnitude greater than 
T47D cells. Serine synthesis accounted for 1.3% of glucose consumption. Remarkably, 96.7% of serine 
supplied by J19 and J20 entered the folate cycle, with only 3.3% exported. Similar to T47D cells, only 2.0% 
of the serine entering the cycle was recycled to the serine pool. The results indicate that the more 
malignant LM cell line has a higher demand for serine, possibly to support greater demand for nucleotide 
synthesis in these rapidly proliferating cells, and this corresponds with a lower rate of serine efflux.  
BoM cells were similar to the LM line in serine labeling pattern (Table 2), folate cycle model-optimized 
flux ratios (Table 5), glucose consumption (Fig 8), and increase in glucose consumption with CBR-5884 
(Fig. 3). In this respect, it was surprising that the fluxes determined using BSO-sensitive glutamine 
consumption were more similar to T47D cells (Table 6, BoMa). Serine synthesis consumed only 0.11% of 
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glucose and 43% of serine supplied by J19 and J20 entered the folate cycle. It is likely that the BSO-
sensitive glutamine uptake substantially underestimates glycine consumption (J23). To test this, an 
alternative approach was taken in which J19 was determined from the fractional M2 serine content and 
glucose consumption using the significant linear regression observed between M2 serine and ratio J19/J0 
for LM and T47D cells (Fig. 7). The fact that data from both cell lines form a single regression line with a 
high correlation coefficient suggests that the relationship between M2 serine and J19/J0 is not unique for 
each cell type and can be applied to BoM cells. From this analysis, J19 was about 80% of that seen in LM 
cells, and 0.96% of glucose was used for serine synthesis (Table 6, BoMb). Approximately 92% of serine 

















Figure 7: Dependence of M2 serine on the ratio of flux through the serine synthesis pathway (J19) to glucose uptake (J0). Data 
from LM and T47D cells were combined and the least-squares regression equation used to calculate J19/J0 for each experiment 









Table 6: Calculated Fluxes within the Folate Cycle 
Cell Line J19 J20 J21 J23 J24 J25 
LM 477 ± 54ᵇ 319 ± 115ᵃ 814 ± 89ᵃ 12131 ± 4605ᵇ 11361 ± 4660ᵃ 44 ± 4ᵃ 
T47D 29 ± 3ᵃ 79 ± 22ᵃ 37 ± 27ᵃ 248 ± 19ᵃ 223 ± 32ᵃ 12 ± 3ᵃ 
BoMᵃ 43 ± 11ᵃ 40 ± 32ᵃ 41 ± 34ᵃ 169 ± 10ᵃ 133 ± 28ᵃ 5 ± 1ᵇ 
BoMᵇ 373 ± 70 197 ± 97 559 ± 47 14526 ± 3879 14004 ± 3910 37 ± 3 
Fluxes are expressed as pmol substrate consumed per minute per mg cell protein. For T47D and BoMa, folate cycle fluxes J19, 
J20, J21, J24, and J25 were calculated from the optimized flux ratios (Table 5), J22 (Fig. 4), and an estimate of J23 from BSO-
sensitive glutamine uptake (see Methods for details). BoMb fluxes were based on an estimate of J19 from the Fig. 7 regression 
plot. For LM cells, the fluxes J20, J21, J23, J24, and J25 were calculated from the optimized flux ratios (Table 5), J22 (Fig. 4), and an 
estimate of J19  from the computational model used to reproduce the 13C lactate labeling pattern. Data are the mean ± the 
standard error of the mean of six experiments for each cell line. Fluxes for LM, T47D, and BoMa were analyzed by 1-way 
ANOVA and Tukey’s post-hoc test. Within a column, means sharing common superscripts are not significantly different. Flux 
notations: J19: serine synthesis from 3PG, J20: serine from protein turnover contributing to cytoplasmic serine pool, J21: de-
methylation of serine in the folate cycle by serine hydroxyl-methyltransferase, J22: serine export to the extracellular fluid, J23: 
cellular glycine consumption, J24: glycine from protein turnover contributing to the cytoplasmic glycine pool, J25: methylation of 






Figure 8: Glucose consumption rates for each cell line measured by metabolite assay. Data are mean ± standard error of the 
mean of six experiments. These rates reflect J0 in the metabolic maps shown in Fig. 1 of the introduction. Data were analyzed by 







The overall goal of this research was to determine if metastatic sub-clones, both derived from the TNBC 
metastatic MDA-MB-231 breast cancer cell line, that preferentially invade and grow in lung or bone 
tissue exhibit metabolic differences in serine and glutathione biosynthesis. Metabolic plasticity is 
potentially important for secondary tumor growth in different tissue microenvironments, and may guide 
development of metastatic tumor-specific, metabolic-targeted therapies. Therefore, fluxes through these 
anabolic pathways were quantified using the principles of 13C metabolic flux analysis with 13C glutamine 
and 13C glucose as substrates.  The major findings from this study were that (a) none of the exogenous 
glutamine consumed by LM cells was used for GSH synthesis compared to approximately 10% used by 
MDA-231, T47D, and BoM lines, (b) LM and BoM lines exhibited relatively high rates of serine 
synthesis, while the parent MDA-231 line had no detectable flux through this pathway, and (c) LM and 
BoM lines exhibited greater folate cycle fluxes than the less malignant T47D line. 
Glutathione is a tripeptide of glutamate, cysteine, and glycine; hence, glutamine consumption through its 
conversion to glutamate, and serine consumption through the folate cycle to glycine, are indirect 
substrates in the production of GSH. GSH becomes oxidized to glutathione disulfide (GSSG) during 
periods of oxidative stress, and the GSH:GSSG ratio is thus an indicator of oxidative stress (25). GSH 
combats oxidative stress by acting as an essential cofactor for a class of enzymes called glutathione 
peroxidases (Gpxs) where it serves as a source of electrons to reduce hydrogen peroxide and lipid 
peroxides to less reactive forms (17, 26). Glutaredoxins (Grx), members of the thioreductase superfamily, 
are GSH-dependent oxidoreductase enzymes that catalyze the thiol-disulfide exchange, primarily from 
GSH to protein thiols or protein disulfides (19, 27). The conversion of GSSG back to its reduced form, 
GSH, is catalyzed by Grxs and glutathione reductases through the oxidation of NADPH, a product of the 
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oxidative pentose phosphate pathway and malic enzyme (17). Grxs’ primary importance is to protect 
protein thiols, the main target of ROS species, from oxidation by adding GSH to the thiol through a 
process called glutathionylation, preventing irreversible oxidation (28).  
Elevated GSH levels are observed in many types of tumors, and they commonly make such tumors more 
resistant to treatment as they prevent oxidative stress triggered by radiation and chemotherapies (29). 
GSH primarily acts as a cytoprotector by preventing damage to proteins or DNA that may induce 
apoptosis, but also by detoxifying other dangerous chemicals within the cell, especially 
chemotherapeutics, allowing GSH to potentially serve as a marker for increased higher risk of metastasis 
(30). One study found that TNBC cells maintained and enhanced Gpx1 expression as opposed to non-
TNBC cell lines; Gpx1 protected focal adhesion kinase (FAK) from oxidation (20). FAK is responsible 
for the critical step of metastasis by creating high affinity binding sites in secondary tissues during 
metastasis, and when it is oxidized, the pathway becomes dysregulated, leading to a reduced proliferation 
of TNBC cells to the lungs (20). This makes the synthesis of glutathione an attractive target for some 
types of metastatic cancers.  
The current study suggests that MDA-231, T47D, and BoM cells use approximately 10% of exogenous 
glutamine for GSH synthesis. Notably, the more metastatic MDA-231 and BoM lines did not exhibit 
higher glutamine demand for GSH than the less aggressive T47D line. This does not exclude the 
possibility that MDA-231 and BoM cells synthesize GSH at a higher rate, as these results do not account 
for use of endogenous glutamate in GSH synthesis. Much of the remaining 90% of glutamine 
consumption is for fatty acid synthesis, ATP production through the TCA cycle, and as a source of 
carbons for reactions such as the malic enzyme pathway which consume TCA metabolites (16).  The LM 
cell line had no detected glutamine consumption for GSH synthesis, which does not support our 
hypothesis that lung-specific tumors have a higher demand for antioxidants such as GSH. The lungs 
having a higher oxygen partial pressure (approximately 100 mmHg) than the systemic tissues (where it 
can range from 20-40 mmHg), which is predicted to increase the probability of superoxide production by 
the mitochondrial respiratory chain (and correspondingly the production of ROS derived from 
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superoxide) in this higher oxygen environment. It is possible that LM cells have sufficient internal 
glutamate and/or glutamine stores to support high rates of GSH synthesis and so do not require exogenous 
glutamine. Alternatively, these cells may have adopted other metabolic features for growth in the lungs; 
they could rely predominantly on peroxyredoxins and thioredoxins, which do not require GSH, for 
defense against ROS, and/or on substrate limitation to mitochondria, which would limit superoxide 
production. The latter possibility is supported by experiments (data not shown) showing that 
mitochondrial respiration rate of LM cells is significantly less than the other three cell lines.  
Serine metabolism is frequently dysregulated in cancers as it serves as a converging point for biosynthesis 
of metabolites that are necessary to fuel the proliferative state of cancers (31). During the biosynthesis of 
serine from 3PG, 2-oxoglutarate is formed from glutamate, which can be used to supply carbons to the 
TCA cycle. Serine is a direct precursor to both glycine and cysteine through the transsulfuration 
pathways, and glycine is directly used in nucleotide base synthesis and glutathione synthesis (31).  Serine 
is a major donor of 1-Carbon units to the folate and methionine cycles as well as the transsulfuration 
pathway. In the folate cycle, serine is converted to glycine by serine hydroxymethyltransferase-2 (SHMT-
2). The carbon 3 methyl group is transferred to tetrahydrofolate (THF) to form methyl-tetrahydrofolate 
(mTHF) (Fig. 6). mTHF links the folate cycle to the methionine cycle by donating its methyl group to 
homocysteine, producing cysteine, a constituent of GSH (33). The folate cycle also helps to maintain 
cellular ATP and GTP levels through de novo purine synthesis (14).  Serine is also required for the 
synthesis of sphingolipids and phosphatidylserine, and the demand for lipids to build lipid membranes of 
growing cells are elevated in cancers (31). Cancers with a higher capacity for serine synthesis and flux 
into the folate cycle (Fig. 5, J21) are thus less reliant on the potentially limited availability of extracellular 
serine for regulation of redox homeostasis, production of nucleotides, and synthesis of lipids and proteins. 
Indeed, recent studies have shown that MDA-231 cells have a low capacity for serine synthesis as their 
growth is completely inhibited in the absence of exogenous serine (32).  
Metabolic profiling in MDA-MB-231 and its tissue-specific subclones to brain (BrM) and bone (BoM) 
have revealed a dependency on serine and the 1-carbon cycles to drive proliferation (34). SHMT-2 
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expression is upregulated in BrM and BoM tissue-specific subclones in comparison to the primary breast 
tumor, and inhibition of the rate-limiting step catalyzed by SHMT-2 suppresses the proliferation of 
metastatic subclones (34). This suggests SHMT-2 activity and upregulation play a direct role in the ability 
of cells in the primary breast tumor to adapt their metabolic phenotype to proliferate and colonize a 
secondary tissue. In the more proliferative BrM and BoM cell lines, Li et al 2020 observed an increase in 
the glycolytic intermediate, dihydroxyacetone-phosphate (DHAP; which can be isomerized the 
glyceraldehyde-3-phosphate, the precursor of 3PG) as well as a significant decrease in free nucleotides in 
comparison to the maternal cell line. . The reduction of free nucleotides is attributed to the elevated 
demand of nucleotides for the BoM and BrM cell lines which have higher proliferation rates. Taken 
together with evidence that inhibition of PHGDH does not affect growth of primary breast tumors but 
does inhibit BrM growth, and that elevated PHGDH expression is necessary for proliferation in serine-
depleted environments, glucose conversion to serine becomes the primary pathway supporting SHMT-2 
activity and the folate cycle (39). Thus, in subclonal, metastatic cell lines, it is a dependency on de-novo 
serine biosynthesis through PHGDH overexpression, as opposed to use of exogenous serine pools in 
parental cells, that fuels serine catabolism pathways that could be important for growth in secondary 
tissue microenvironments (39).  
PHGDH expression and 13C enrichment in serine from glucose in the MDA-MB-231 cell line are low 
compared to many cancers, showing this cell line has little to no de novo serine biosynthesis (35, 36). 
Furthermore, without exogenous serine in the media, proliferation of MDA-231 cells is significantly 
inhibited, whereas other cell lines with a high capacity for serine synthesis are unaffected (21, 34). The 
present results confirm these findings, as there was no detectable 13C labeling of serine in the MDA-231 
cells above background 13C (Table 2). The enhanced de novo serine biosynthesis in LM and BoM cells, 
indicates that extracellular serine availability is not a limitation to growth in their respective 
microenvironments. Given that LM and BoM have higher proliferation rates compared to the MDA-231 
parent line, this metabolic change is likely advantageous for the cell lines to adopt a more aggressive 
phenotype. While BoM cells did not synthesize serine at a higher rate than the LM line as originally 
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hypothesized, this pathway may be particularly important for BoM cells, as extracellular serine 
availability may be particularly limiting given that mass-adjusted blood flow to bone is approximately 
150-250-fold lower than that to the lungs (37). Additionally, serine stimulates the production of 
osteoclasts, which mediate bone demineralization and degradation (38). Serine produced in excess of that 
needed for proliferation and exported from cells could thus contribute to bone destruction. 
Serine synthesis was also detected in T47D cells, but the pattern of 13C enrichment differed from LM and 
BoM lines, suggesting the rates of synthesis and/or the recycling of serine through the folate cycle differ 
(Table 2). In support of this, the BoM and LM cells exhibited similar increases in glucose consumption 
when serine synthesis was inhibited with CBR-5884, but the T47D cells did not (Fig 3). While a decrease 
in glucose consumption was expected, the results are consistent with the possibility that NADH 
production by the serine pathway is sufficiently robust in LM and BoM lines to inhibit glycolysis by 
increasing the cytoplasmic NADH:NAD ratio, which is an allosteric regulator of glycolysis. Glycolytic 
production of NADH leads to stoichiometric production of pyruvate, which can subsequently be reduced 
to lactate by the NADH-dependent lactate dehydrogenase; thus, when a high proportion of pyruvate is 
reduced to lactate, as in most cancers, this flux tends to lower the NADH:NAD ratio. With the serine 
synthesis pathway active, NADH is produced but pyruvate is not, so the resulting NADH may not be 
required by lactate dehydrogenase, thereby potentially increasing the NADH:NAD ratio. Relieving such 
allosteric inhibition with CBR-5884 could more than offset the reduction in glucose uptake due to loss of 
3PG conversion to serine. Alternatively, it is possible that 3PG flux to serine does not differ between 
these three lines, but that LM and BoM glycolytic enzymes are more sensitive to allosteric inhibition by 
NADH than the same enzymes in T47D cells. However, the differences in 13C serine enrichment between 
these lines (particularly M2 content; see Fig. 7) suggests the 3PG to serine fluxes differ and that such a 
difference impacts NADH:NAD and allosteric regulation of glycolysis.  This is further supported by the 
folate cycle predicted contribution of serine synthesis to labeling the cytoplasmic serine pool  (J19 /(J19+ 
J20); Table 5).  Serine synthesis accounted for approximately 30% of the serine production in T47D cells 
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compared to 64-69% for LM and BoM cells. Taken together, these data indicate a more active serine 
synthesis pathway in LM and BoM cells than T47D cells.  
The flux of 3PG to serine and all folate cycle fluxes for T47D and BoM cells were determined from the 
measured 13C serine labeling pattern, the model-inferred 3PG 13C labeling pattern, the model-inferred 
folate cycle flux ratios, the serine efflux rate (J22), and the BSO-sensitive glutamine uptake rate, the latter 
of which is an estimate of glycine consumption for GSH synthesis (J23). The true glycine consumption is 
likely higher than this since it does not account for other reactions (e.g., glycine export) that use this 
amino acid; in turn, this may underestimate serine synthesis flux. Only 0.13% of glucose consumed by 
T47D cells was used to synthesize serine. A detailed study of amino acid uptake rates and protein 
synthesis rate in T47D cells by Dolfi et al (2013) allowed an alternative estimate of cellular glycine 
consumption (J23). From their data, we calculated that T47D serine demand was 5.16% of glucose uptake, 
but 3.42% of glucose uptake without protein synthesis. The latter was used to estimate T47D serine 
consumption through the folate cycle (i.e., J23= J0*0.0342 – J22) and hence serine synthesis flux in the 
current experiments since little to no protein synthesis is expected in the absence of essential amino acids. 
There was good agreement between these approaches (3PG conversion to serine averaged 29±3 and 31±3 
pmol/min x mg using BSO-sensitive glutamine uptake and Dolfi et al data, respectively), suggesting that 
the use of BSO-sensitive glutamine consumption, at least for T47D cells, is a reasonable approximation of 
J23. However, this analysis yielded a similarly low 3PG to serine flux for BoM cells (43±11 pmol/min x 
mg; Table 6), despite evidence from the CBR-5884 experiments and 13C serine enrichment implicating a 
higher flux; thus the BSO-sensitive glutamine consumption is likely a significant underestimate of J23, 
and hence J19, in BoM cells. As an alternative approach, 3PG to serine flux was calculated from the 
measured M2 serine content (Table 2) using the significant positive correlation between the fraction of 
serine M2 and the ratio of serine synthesis to glucose uptake for LM and T47D cells (Fig. 7). By this 
approach, serine synthesis was an order of magnitude greater than that estimated by BSO-sensitive 
glutamine uptake (0.92% of glucose converted to serine) and similar to LM cells (1.3% of glucose 
converted to serine). Serine consumption by the folate cycle was approximately two orders of magnitude 
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greater than the previous estimate, and suggests glycine efflux is considerably greater than serine efflux. 
The results are consistent with the CBR-5884 experiments and 13C serine labeling and thus a better 
approximation of the fluxes.  
Glycine demand for GSH synthesis could not be estimated for LM cells since they lacked a BSO-
sensitive glutamine consumption. Notably, the model developed to reproduce 13C lactate enrichment from 
[1,2-13C] glucose was ineffective assuming no 3PG to serine flux, as this constrained malic enzyme flux, 
which is the pathway most important for enriching M1 and M3 lactate as carbons are shuffled in the TCA 
cycle. This constraint occurs because the only two pyruvate producers in the model are glycolysis and 
malic enzyme, and these must balance the rates of pyruvate consumed by lactate dehydrogenase and 
mitochondria (Fig. 1). Increased malic enzyme flux, by necessity, reduces glycolytic pyruvate and thus 
NADH supply; however, a minimum rate of NADH supply, set by the measured rate of lactate 
production, is necessary. Serine synthesis was therefore determined by the model as the flux necessary to 
supply NADH at a rate sufficient for malic enzyme to minimize the error in reproducing 13C lactate 
labeling. This indicates that serine biosynthesis is an important source of NADH production for lactate 
production, as it is required for the reduction of malate-generated pyruvate into lactate. Also, the 
production of 2-oxoglutarate during biosynthesis of serine may be used a source of carbons to produce 
malate, which is catalyzed by malic enzyme into pyruvate. The malic enzyme pathway also generates 
NADPH, the reducing equivalent used by Gpxs alongside GSH to provide antioxidant defense for protein 
thiols. Because J19 was established in this way, it likely underestimates the true flux given that NADH 
production is expected to be greater than the rate of malic enzyme flux if it is to significantly increase the 

















In summary, the results do not support the hypothesis that BoM cells have higher rates of serine synthesis 
than the other cell lines; the higher serine synthesis rates and folate cycle fluxes in both LM and BoM 
subclones are likely important to support their higher rates of proliferation than the MDA-231 and T47D 
lines by increasing substrate availability for purine nucleotide synthesis, and/or increasing NADH and a-
ketoglutarate synthesis to support the TCA cycle and malic enzyme. The results did not support the 
hypothesis that LM cells have a higher rate of GSH synthesis and a higher proportion of glutamine used 
for GSH synthesis to protect against the more oxygen-rich lung microenvironment. This surprising result 
suggests that LM cells may rely on peroxiredoxins and/or thioredoxins as antioxidant defense 
mechanisms rather than on glutathione peroxidases and glutaredoxins. Since the T47D cell line is 
characterized as being less metastatic and slower to proliferate than LM and BoM cell lines, the 
biosynthetic and metabolic requirements to fuel its proliferation will be less. The reduced glucose 
consumption seen in T47D cells comparatively as well as the significantly lower flux of 3-
phosphoglycerate to serine, confirms the notion that T47D cells require less serine biosynthesis for 
various biosynthetic reactions within the 1-Carbon cycle that contribute to GSH, fatty acid, NAD(P)H, 
and amino acid production. Taken together, these differences illustrate there are changes in metabolic 
phenotype among these metastatic breast cancer subclones. More studies are required to determine if 
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